Hsbc Holdings PLC Makes New $36,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN)

Hsbc Holdings PLC acquired a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 11,663 shares of the company’s stock, valued at approximately $36,000.

Other hedge funds also recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in Acelyrin during the 4th quarter worth $33,000. RPO LLC acquired a new position in shares of Acelyrin in the 4th quarter valued at about $46,000. Intech Investment Management LLC boosted its holdings in shares of Acelyrin by 71.0% in the 4th quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock valued at $83,000 after buying an additional 11,040 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Acelyrin by 21.9% in the 4th quarter. Wells Fargo & Company MN now owns 52,014 shares of the company’s stock valued at $163,000 after buying an additional 9,332 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Acelyrin by 146.0% in the 4th quarter. American Century Companies Inc. now owns 78,868 shares of the company’s stock valued at $248,000 after buying an additional 46,802 shares during the period. 87.31% of the stock is owned by institutional investors and hedge funds.

Acelyrin Stock Performance

NASDAQ SLRN opened at $2.48 on Tuesday. Acelyrin, Inc. has a one year low of $1.85 and a one year high of $7.25. The company has a 50-day simple moving average of $2.45 and a 200-day simple moving average of $3.07. The firm has a market capitalization of $250.25 million, a PE ratio of -1.01 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.07. Equities analysts forecast that Acelyrin, Inc. will post -2.53 earnings per share for the current year.

Insider Activity

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the transaction, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at $1,840,603.22. The trade was a 2.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 13.60% of the company’s stock.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.